Milrinon Stragen (Milrinone)

Milrinone, the active ingredient in Milrinon Stragen, is a phosphodiesterase 3 inhibitor presented as an intravenous solution for intravenous use. It enhances cardiac contractility in hospitalized patients with acute decompensated heart failure or cardiogenic shock, providing critical rapid hemodynamic support.

GNH USA supplies Milrinon Stragen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and clinics worldwide, with a focus on quality assurance, regulatory compliance and timely delivery to meet the needs of cardiac care units across globally.

Milrinone is used in the management of acute heart‑failure syndromes that involve impaired cardiac contractility.

- Acute decompensated heart failure: improves cardiac output and reduces pulmonary congestion. - Cardiogenic shock: provides rapid inotropic support to maintain systemic perfusion. - Post‑cardiac surgery low‑output syndrome: enhances myocardial contractility to support hemodynamics.

Milrinone may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea or vomiting: gastrointestinal discomfort. - Arrhythmias: premature ventricular beats. - Hypotension: transient drop in blood pressure.

Serious or Rare Side Effects: - Severe ventricular tachycardia or fibrillation. - Myocardial ischemia: chest pain with ECG changes. - Thrombocytopenia: low platelet count. - Anaphylactic reaction: severe hypersensitivity.

When using Milrinone, clinicians should observe specific precautions to minimize risks and ensure safe administration. - Cardiac monitoring: continuous ECG and blood pressure monitoring is required during infusion. - Electrolyte balance: correct hypokalemia and hypomagnesemia before starting therapy. - Renal impairment: adjust infusion rate in severe renal dysfunction. - Concomitant vasodilators: use cautiously as additive hypotensive effects may occur. - Pregnancy and lactation: avoid unless benefit outweighs potential risk, as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Milrinone can interact with several medications, influencing its efficacy or safety profile.

Major Interactions (Avoid): - Beta‑blockers: may blunt the inotropic response, reducing therapeutic effect. - Strong CYP3A4 inhibitors (e.g., ketoconazole): can increase plasma concentrations, raising risk of toxicity.

Moderate Interactions (Monitor Closely): - Diuretics: may exacerbate electrolyte disturbances, increasing arrhythmia risk. - Other inotropes (e.g., dobutamine): additive cardiovascular effects require dose adjustment. - Anticoagulants: heightened bleeding risk if thrombocytopenia develops.